# A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

> **NCT06533098** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 50 (estimated)

## Conditions studied

- Thrombocytopenia, Neonatal Alloimmune

## Interventions

- **DRUG:** Nipocalimab
- **DRUG:** Intravenous immunoglobulins (IVIG)
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06533098
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2027-12-15
- **Final completion:** 2029-12-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533098, "A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06533098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*